On the upside
The Food and Drug Administration granted orphan drug status to Cell Therapeutics' (Nasdaq: CTIC) brain cancer treatment Opaxio.
AMD (NYSE: AMD) introduced its second generation AMD A-Series Accelerated Processing Units for desktop, small form-factor and home theater PCs.
On the downside
ArQule (Nasdaq: ARQL) ended a Phase 3 MARQUEE clinical trial for failing to increase overall survival.
Express (NYSE: EXPR) cut its earnings guidance for the third quarter as traffic in September weakend and the clothing retailer discounted more.
Fifth & Pacific (NYSE: FNP) blamed weakness in its Juicy Courture brand for lowering its full year forecast.
In the broad market, advancing issues outpaced decliners by a margin of nearly 5 to 4 on the NYSE and by more than 9 to 7 on Nasdaq. The Russell 2000 which tracks small cap stocks eased a fraction to 839.